Sangsuwannukul’s group developed a novel fourth-generation CAR133-T and tested its efficacy in high CD133-expressing human cholangiocarcinoma (CCA) cell line (KKU-213A cells). This evidence concerns the gene PROM1 and cholangiocarcinoma.